Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

JAMA Netw Open. 2020 Oct 1;3(10):e2020969. doi: 10.1001/jamanetworkopen.2020.20969.

Abstract

This cross-sectional study assesses drug coverage, formulary restrictions, median retail prices, and annual out-of-pocket costs associated with commonly used insulin products across Medicare Part D plans.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / economics
  • Drug Costs
  • Glycated Hemoglobin
  • Health Expenditures* / statistics & numerical data
  • Humans
  • Hypoglycemic Agents* / economics
  • Hypoglycemic Agents* / therapeutic use
  • Insurance, Pharmaceutical Services / economics
  • Medicare Part D* / economics
  • Sodium-Glucose Transporter 2 Inhibitors* / economics
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • United States

Substances

  • Glycated Hemoglobin
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors